Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Drug Stores and Retail Pharmacies (Fastest-Growing Segment)

The hospital pharmacies segment dominated the hepatitis therapeutics market, accounting for a 55.81% share in 2026, supported by the substantial need for specialized hepatitis therapies within hospital-based treatment pathways. Hospitals provide access to physicians, diagnostic facilities, and monitoring services required for patients receiving complex antiviral and supportive treatments. The concentration of specialized care and prescription management within hospital settings also enables coordinated treatment and follow-up, particularly for patients with advanced or complicated disease. Continued emphasis on comprehensive hepatitis management and timely access to prescribed therapies is reinforcing the importance of hospital pharmacies.

Drug stores and retail pharmacies are expected to grow at the fastest pace as hepatitis treatment increasingly extends into outpatient and community-based care settings. These channels provide patients with greater convenience and easier access to prescribed therapies, supporting treatment continuity outside hospitals. Growing awareness of hepatitis screening and treatment is encouraging more patients to seek care earlier, while expanding access to oral therapies is making community-based dispensing increasingly relevant. The broader shift toward decentralized healthcare delivery and patient-centered treatment is expected to strengthen demand through drug stores and retail pharmacies.

Disease Segment Analysis: Hepatitis C (Largest Segment) vs Hepatitis B (Fastest-Growing Segment)

Hepatitis C held the largest position in the hepatitis therapeutics market, accounting for a 79.38% share in 2026, driven by the substantial treatment demand associated with chronic infection and the availability of increasingly effective therapeutic approaches. Advances in antiviral treatment have improved the ability to achieve sustained viral clearance, strengthening the role of pharmacological intervention in disease management. Greater emphasis on screening and identifying undiagnosed infections is also supporting treatment uptake by bringing more patients into care pathways. Continued attention to eliminating hepatitis C as a significant public health burden is reinforcing demand for therapeutic solutions.

The hepatitis B segment is anticipated to register the fastest growth as healthcare systems place greater emphasis on long-term disease management, early diagnosis, and prevention of complications associated with chronic infection. Improved screening programs are helping identify patients who require ongoing monitoring and treatment, while advances in antiviral therapies are supporting more effective disease control. Increasing awareness of hepatitis B transmission and the importance of regular clinical management is also encouraging broader engagement with healthcare services. As treatment access improves and disease management becomes more structured, demand for hepatitis B therapeutics is expected to expand.